The Valley Desk

ArticleThe journal of allergy and clinical immunology. In practicePublished

Mepolizumab reduces oral corticosteroid use across distinct severe asthma phenotypes: 2-year REALITI-A study

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names GSK. Affiliation source

Institution
GSK

Publication record

Type
Article
Venue
The journal of allergy and clinical immunology. In practice
Published
Subject terms
IgE; Severe asthma; Mepolizumab; Real World; Oral Corticosteroid; Atopic Status; Baseline Blood Eosinophil Count; Baseline Feno; Omalizumab Eligibility; Realiti-a
PubMed ID
42918296
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal